|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sankaranarayanan R and Ferlay J: Worldwide
burden of gynaecological cancer: The size of the problem. Best
Pract Res Clin Obstet Gynaecol. 20:207–225. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boya P, González-Polo RA, Casares N,
Perfettini JL, Dessen P, Larochette N, Métivier D, Meley D,
Souquere S, Yoshimori T, et al: Inhibition of macroautophagy
triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qi XF, Kim DH, Lee KJ, Kim CS, Song SB,
Cai DQ and Kim SK: Autophagy contributes to apoptosis in A20 and
EL4 lymphoma cells treated with fluvastatin. Cancer Cell Int.
13:1112013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kondo Y, Kanzawa T, Sawaya R and Kondo S:
The role of autophagy in cancer development and response to
therapy. Nat Rev Cancer. 5:726–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mathew R, Karantza-Wadsworth V and White
E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jung CH, Ro SH, Cao J, Otto NM and Kim DH:
mTOR regulation of autophagy. FEBS Lett. 584:1287–1295. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ganley IG, Lam du H, Wang J, Ding X, Chen
S and Jiang X: ULK1 ATG13. FIP200 complex mediates mTOR signaling
and is essential for autophagy. J Biol Chem. 284:12297–12305. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hippert MM, O'Toole PS and Thorburn A:
Autophagy in cancer: Good, bad, or both? Cancer Res. 66:9349–9351.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lévy A, Sauvin LA, Massard C and Soria JC:
Everolimus (RAD001) and solid tumours: A 2008 summary. Bull Cancer.
95:1205–1211. 2008.(In French). PubMed/NCBI
|
|
13
|
Agarwala SS and Case S: Everolimus
(RAD001) in the treatment of advanced renal cell carcinoma: A
review. Oncologist. 15:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beuvink I, Boulay A, Fumagalli S,
Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA and
Thomas G: The mTOR inhibitor RAD001 sensitizes tumor cells to
DNA-damaged induced apoptosis through inhibition of p21
translation. Cell. 120:747–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weigelt B and Downward J: Genomic
determinants of PI3K pathway inhibitor response in cancer. Front
Oncol. 2:1092012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dengler J, von Bubnoff N, Decker T,
Peschel C and Duyster J: Combination of imatinib with rapamycin or
RAD001 acts synergistically only in Bcr-Abl-positive cells with
moderate resistance to imatinib. Leukemia. 19:1835–1838. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao C, Subhawong T, Albert JM, Kim KW,
Geng L, Sekhar KR, Gi YJ and Lu B: Inhibition of mammalian target
of rapamycin or apoptotic pathway induces autophagy and
radiosensitizes PTEN null prostate cancer cells. Cancer Res.
66:10040–10047. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shinohara ET, Cao C, Niermann K, Mu Y,
Zeng F, Hallahan DE and Lu B: Enhanced radiation damage of tumor
vasculature by mTOR inhibitors. Oncogene. 24:5414–5422. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haritunians T, Mori A, O'Kelly J, Luong
QT, Giles FJ and Koeffler HP: Antiproliferative activity of RAD001
(everolimus) as a single agent and combined with other agents in
mantle cell lymphoma. Leukemia. 21:333–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Panner A, Parsa AT and Pieper RO: Use of
APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma
multiforme. Expert Rev Anticancer Ther. 6:1313–1322. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mayer IA, Burris H, Bendel J, Means-Powell
J, Arteaga C, Shyr Y and Pietenpol J: A phase Ib trial of RAD001,
an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients
with HER2-negative metastatic breast cancer. Abstract 3093. 32nd
Annual San Antonio Breast Cancer Symposium. San Antonio, TX.
December 9–13, 2009;
|
|
22
|
Mason RL, Gunst RF and Hess JJ:
Statistical Design and Analysis of ExperimentsWith Applications to
Engineering and Science. 2nd. John Wiley and Sons Inc.; Hoboken,
NJ: 2003
|
|
23
|
Tanida I, Ueno T and Kominami E: LC3 and
autophagy. Methods Mol Biol. 445:77–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sever R and Brugge JS: Signal transduction
in cancer. Cold Spring Harb Perspect Med. 5:a0060982015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kolch W, Halasz M, Granovskaya M and
Kholodenko BN: The dynamic control of signal transduction networks
in cancer cells. Nat Rev Cancer. 15:515–527. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ranjan A, Fofaria NM, Kim SH and
Srivastava SK: Modulation of signal transduction pathways by
natural compounds in cancer. Chin J Nat Med. 13:730–742.
2015.PubMed/NCBI
|
|
27
|
Zhou HY and Huang SL: Current development
of the second generation of mTOR inhibitors as anticancer agents.
Chin J Cancer. 31:8–18. 2012.PubMed/NCBI
|
|
28
|
Tan HK, Moad AI and Tan ML: The mTOR
signalling pathway in cancer and the potential mTOR inhibitory
activities of natural phytochemicals. Asian Pac J Cancer Prev.
15:6463–6475. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ozols RF: Paclitaxel (Taxol)/carboplatin
combination chemotherapy in the treatment of advanced ovarian
cancer. Semin Oncol 27 (Suppl 7). 3–7. 2000.
|
|
30
|
Okamoto I, Moriyama E, Fujii S, Kishi H,
Nomura M, Goto E, Kiyofuji C, Imamura F, Mori T and Matsumoto M:
Phase II study of carboplatin-paclitaxel combination chemotherapy
in elderly patients with advanced non-small cell lung cancer. Jpn J
Clin Oncol. 35:188–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pentheroudakis G, Razis E, Athanassiadis
A, Pavlidis N and Fountzilas G: Paclitaxel-carboplatin combination
chemotherapy in advanced breast cancer: Accumulating evidence for
synergy, efficacy, and safety. Med Oncol. 23:147–160. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yardley DA, Brufsky A, Coleman RE, Conte
PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A,
et al: Phase II/III weekly nab-paclitaxel plus gemcitabine or
carboplatin versus gemcitabine/carboplatin as first-line treatment
of patients with metastatic triple-negative breast cancer (the
tnAcity study): Study protocol for a randomized controlled trial.
Trials. 16:5752015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamazaki S, Sekine I and Saijo N:
Paclitaxel (taxol): A review of its antitumor activity and toxicity
in clinical studies. Gan To Kagaku Ryoho. 25:605–615. 1998.(In
Japanese). PubMed/NCBI
|
|
34
|
Liu H, Chen X, Sun J, Gao P, Song Y, Zhang
N, Lu X, Xu H and Wang Z: The efficacy and toxicity of paclitaxel
plus S-1 compared with paclitaxel plus 5-FU for advanced gastric
cancer: A PRISMA systematic review and meta-analysis of randomized
controlled trials. Medicine (Baltimore). 93:e1642014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dufour M, Dormond-Meuwly A, Demartines N
and Dormond O: Targeting the Mammalian Target of Rapamycin (mTOR)
in Cancer Therapy: Lessons from Past and Future Perspectives.
Cancers (Basel). 3:2478–2500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mizushima N: Autophagy: Process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Berry DL and Baehrecke EH: Autophagy
functions in programmed cell death. Autophagy. 4:359–360. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Alonso S, Pethe K, Russell DG and Purdy
GE: Lysosomal killing of Mycobacterium mediated by
ubiquitin-derived peptides is enhanced by autophagy. Proc Natl Acad
Sci USA. 104:6031–6036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lum JJ, Bauer DE, Kong M, Harris MH, Li C,
Lindsten T and Thompson CB: Growth factor regulation of autophagy
and cell survival in the absence of apoptosis. Cell. 120:237–248.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Park HJ, Lee SJ, Kim SH, Han J, Bae J, Kim
SJ, Park CG and Chun T: IL-10 inhibits the starvation induced
autophagy in macrophages via class I phosphatidylinositol 3-kinase
(PI3K) pathway. Mol Immunol. 48:720–727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pattingre S, Tassa A, Qu X, Garuti R,
Liang XH, Mizushima N, Packer M, Schneider MD and Levine B: Bcl-2
antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell.
122:927–939. 2005. View Article : Google Scholar : PubMed/NCBI
|
